Lemna Bio

Lemna Bio is a Swiss biotechnology company that develops an atomic-resolution AI framework designed to decode and encode biological interactions for preclinical drug discovery. Their technology is built upon a geometric transformer model that reasons from first principles using atomic structures, combined with biological context to explain mechanisms of disease and drug action. The platform, which features tools such as Pesto for predicting interaction interfaces and Carbonara for protein sequence design, aims to provide explainable hypotheses that assist research teams in mapping disease pathways, assessing target druggability, and identifying safe, effective drug candidates. By integrating physics-grounded modeling with computational biology, the company seeks to address high failure rates, costs, and timelines in the early stages of drug development.

The company's offerings are designed to empower biopharma partners and researchers to make more informed, data-driven decisions throughout the drug discovery process. Lemna Bio pursues a dual-pronged commercial strategy consisting of fee-for-service engagements and early-stage partnerships. Their models have been utilized by thousands of researchers, and their sequence design capabilities have received industry benchmarking. Headquartered in Lausanne, Switzerland, the company is supported by various incubators and accelerators, including Venture Kick and the DayOne Accelerator, and focuses on novel molecular formats with therapeutic potential to overcome current industry limitations in target selection and drug mechanism validation.